Study design of the included studies
| Study | Year | MCS group/non-MCS group | No of Patients | Stenting, % | BMS, % | PCI success, % | Timing of MCS | Time point of reported mortality | Follow-up |
| SEMPER FI25 | 2020 | IABP+stenting/stenting | 50/50 | 100 | NA | 90/96 | After stenting | 30 days, 6 months | 6 months |
| Zhou et al29 | 2017 | IABP+stenting/stenting | 42/42 | 100 | NA | NA | Before stenting | In-hospital, 12 months | 12 months |
| IABP-SHOCK II8 9 | 2012, 2013 | IABP+stenting/stenting | 301/299 | 89.8 | 50.2/51.5 | 82.2/81.5 | Before or after stenting | 30 days, 6 months | 6 years |
| CRISP AMI28 | 2011 | IABP+stenting/stenting | 161/176 | 96.9 | 53.7/53.1 | 92.9/95.3 | Before stenting | 30 days, 6 months | 6 months |
| Gu et al30 | 2011 | IABP+stenting/stenting | 51/55 | 100 | NA | NA | Before stenting | 30 days, 6 months | 6 months |
| Prondzinsky et al31 | 2010 | IABP+stenting/stenting | 19/21 | 85 | NA | NA | After stenting | In-hospital | In-hospital |
| Arias et al33 | 2005 | IABP+stenting/stenting | 31/9 | 100 | NA | NA | Before stenting | In-hospital | In-hospital |
| Vijayalakshmi et al34 | 2007 | IABP+stenting/stenting | 17/16 | 100 | NA | NA | After stenting | In-hospital, 30 days | 30 days |
| IMPRESS26 | 2017 | pVADs+stenting/IABP+stenting | 24/24 | 97.9 | 4/8 | NA | After stenting | 30 days, 6 months | 6 months |
| Seyfarth et al32 | 2008 | pVADs+stenting/IABP+stenting | 13/13 | NA | NA | 100/92 | After stenting | 30 days | 30 days |
| Thiele et al27 | 2005 | pVADs+stenting/IABP+stenting | 21/20 | 95.1 | NA | 80/74 | Before or after stenting | 30 days | 30 days |
| Lackermair et al35 | 2020 | ECLS+stenting/stenting | 21/21 | 100 | NA | NA | After stenting | 30 days, 12 months | 12 months |
BMS, bare-metal stent; ECLS, extracorporeal life support; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; NA, not available; PCI, percutaneous coronary intervention, including stenting and balloon angioplasty; pVADs, percutaneous ventricular assist devices.